MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development

MEDIPOST, Inc. announced that its parent company, MEDIPOST Co., Ltd., has closed on $140 million in funding. The investment will accelerate the company’s Phase III trial of its investigational MSC therapy to treat symptomatic cartilage defects in patients with knee osteoarthritis.